News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
696,446 Results
Type
Article (45631)
Company Profile (213)
Press Release (650602)
Section
Business (207911)
Career Advice (2135)
Deals (35928)
Drug Delivery (91)
Drug Development (81745)
Employer Resources (185)
FDA (16102)
Job Trends (15144)
News (350095)
Policy (33089)
Tag
Academia (2713)
Africa (783)
Allergies (39)
Alliances (50412)
Alzheimer's disease (1131)
Antibody-drug conjugate (ADC) (50)
Approvals (16041)
Arizona (166)
Artificial intelligence (57)
Asia (38236)
Australia (6258)
Bankruptcy (355)
Best Places to Work (11355)
Biosimilars (57)
C2C Services and Suppliers (80724)
California (827)
Canada (643)
Cancer (195)
Career advice (1791)
CAR-T (40)
Cell therapy (76)
China (50)
Clinical research (63288)
Collaboration (66)
Colorado (36)
COVID-19 (2532)
Cystic fibrosis (70)
Diabetes (34)
Diagnostics (6032)
Diversity, equity & inclusion (47)
Drug pricing (56)
Earnings (83595)
Employer resources (155)
Europe (82682)
Events (110342)
FDA (16147)
Florida (106)
Funding (39)
Gene therapy (62)
GLP-1 (511)
Government (4421)
Healthcare (18896)
Hotbed/Location (490672)
Idaho (56)
Illinois (208)
Indiana (107)
Infectious disease (2547)
Inflammatory bowel disease (88)
Interviews (338)
IPO (16321)
Job creations (3828)
Job search strategy (1557)
Kansas (92)
Layoffs (392)
Legal (7971)
Liver cancer (52)
Lung cancer (44)
Maine (47)
Management (57)
Manufacturing (52)
Maryland (258)
Massachusetts (453)
Medical device (13095)
Medtech (13098)
Mergers & acquisitions (19303)
Metabolic disorders (175)
Neuroscience (1220)
New Jersey (63)
New York (84)
NextGen Class of 2024 (6641)
Non-profit (4606)
North Carolina (168)
Obesity (119)
Opinion (176)
Parkinson's disease (31)
Patents (36)
Peanut (35)
Pennsylvania (55)
People (57476)
Phase I (19622)
Phase II (27866)
Phase III (20837)
Podcasts (35)
Policy (36)
Postmarket research (2624)
Preclinical (8590)
Rare diseases (91)
Real estate (6195)
Recruiting (69)
Regulatory (21439)
Reports (40)
Research institute (2452)
Resumes & cover letters (368)
South America (1160)
Startups (3749)
Texas (89)
United States (3071)
Vaccines (434)
Washington State (114)
Weight loss (114)
Date
Today (74)
Last 7 days (502)
Last 30 days (1943)
Last 365 days (39140)
2024 (22132)
2023 (40858)
2022 (51925)
2021 (56502)
2020 (54903)
2019 (47649)
2018 (35938)
2017 (33087)
2016 (32665)
2015 (38769)
2014 (32375)
2013 (27537)
2012 (29798)
2011 (30535)
2010 (29032)
696,446 Results for "dermavant sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
Dermavant Sciences has received approval in Japan for tapinarof cream, 1% for the treatment of both adults with psoriasis and patients 12 years of age and older with atopic dermatitis.
June 25, 2024
·
5 min read
Drug Development
Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD
Dermavant Sciences today announced that the data from ADORING 1 and ADORING 2, two identical, double-blind, randomized, vehicle-controlled pivotal Phase 3 trials of VTAMA® (tapinarof) cream, 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology.
May 21, 2024
·
8 min read
Biotech Beach
Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Dermavant Sciences today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older.
April 29, 2024
·
5 min read
Drug Development
Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
Dermavant Sciences announced that new ADORING data including treatment of patients with skin of color from Phase 3 trials of VTAMA® cream, 1% in adults and children 2 years of age and older with atopic dermatitis will be presented at the 2024 American Academy of Dermatology Annual Meeting, to be held from March 8-12 in San Diego, California.
March 1, 2024
·
6 min read
Biotech Beach
Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VTAMA® (tapinarof) cream.
February 14, 2024
·
7 min read
Business
Dermavant Champions a Culture that Earns Three Best Workplace Rankings in 2023 by Fortune and Great Place to Work®
Dermavant Sciences announced that the company has been named one of 2023’s Best Workplaces for Millennials™, Best Medium Workplaces™ and Best Workplaces in BioPharma™ by Fortune magazine and Great Place to Work® — Dermavant’s eighth recognition by the organizations.
October 13, 2023
·
6 min read
Business
Dermavant Appoints John Darden as New Head of Marketing
Dermavant Sciences today announced the appointment of John Darden as Vice President of Marketing. Darden brings more than 15 years of sales, marketing and market access experience in dermatology and immunology.
October 5, 2023
·
3 min read
Drug Development
Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced new positive efficacy and safety data from analyses of the company’s ADORING Phase 3 development program in atopic dermatitis.
January 11, 2024
·
10 min read
Drug Development
Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults & Children 2 Years of Age & Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
Dermavant Sciences announced new data on treatment of patients with skin of color from its Phase 3, ADORING 1 and ADORING 2 pivotal trials of VTAMA® cream, 1% in adults and children 2 years of age and older with atopic dermatitis at the 2024 American Academy of Dermatology Annual Meeting, being held from March 8-12 in San Diego, CA.
March 8, 2024
·
8 min read
Drug Development
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive results from its Phase 4, open-label clinical trial of VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in the head and neck region in adults (N=31).
December 6, 2023
·
10 min read
1 of 69,645
Next